CSL Of Australia Could Face Roadblock To U.S. Approval Of Talecris Buy
This article was originally published in PharmAsia News
Executive SummaryAustralia's CSL may have trouble getting the approval of U.S. authorities for its acquisition of Talecris Biotherapeutics. The $3.1 billion deal for the blood products company was announced last August, but at least one analyst noted U.S. administrations have changed since then to give greater attention to regulation. The fear is the Federal Trade Commission will block the merger because it would give CSL too much of the blood products market. (Click here for more
You may also be interested in...
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.